Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression on frontline atezolizumab and bevacizumab to targeted therapy or another TKI based on identified genomic alterations.
Toronto, ON (PRWEB) June 09, 2022 Immunotherapy has emerged as the most promising cancer treatment in the last decade with a major impact in oncology by
Lunaphore Technologies S.A.: Lunaphore Announces Formation of New Scientific Advisory Board
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the formation of its Scientific Advisory Board (SAB) with the appointment of two experts in the immuno-oncology (I-O) field to provide strategic advisory support to the company s R&D activities and product portfolio development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005435/en/
Dr. Jerome Galon Member of Lunaphore Scientific Advisory Board (Photo: Business Wire)
The role of the SAB will be to bring strategic insights that will enable Lunaphore to become leaders in the field of high-dimensional analysis of tissue samples. The SAB will support as well in the establishment of scientific partnerships with key stakeholders for the coming years.